organization · Reporting owner
Everest Aggregator, LP
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Camp4 Therapeutics CorpCAMP · Entity 1161 | 10% owner | October 15, 2024 | October 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Camp4 Therapeutics Corp
Report date October 15, 2024 · Filed October 17, 2024
Jointly reported with ENAVATE SCIENCES GP, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Everest Aggregator, LP | 3,785,802 |
Last balance in matching sequence
After 2024-10-15 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-10-15 · Conversion · Acquired 2,422,166 · Balance 2,422,166 F1: Each share of Series B Preferred Stock (the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date. F2: Shares are directly held by Everest Aggregator, LP ("Everest"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Row 2 · 2024-10-15 · Purchase · Acquired 1,363,636 · Balance 3,785,802 F2: Shares are directly held by Everest Aggregator, LP ("Everest"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Everest Aggregator, LP | 0 |
Reported balance
After 2024-10-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-10-15 · Conversion · Disposed 27,166,530 · Balance 0 F1: Each share of Series B Preferred Stock (the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date. F2: Shares are directly held by Everest Aggregator, LP ("Everest"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Preferred Stock (the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
F2: Shares are directly held by Everest Aggregator, LP ("Everest"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2024 Filed Oct 17, 2024 16:15 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries B Preferred Stock · Derivative | 27,166,530 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-025354 · form4-10172024_041001.xml · derivative · entry 3 Enavate Sciences GP, LLC · CIK 0001953107 · 10% owner Everest Aggregator, LP · CIK 0002040426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Everest Aggregator, LP Disclosed balance after: 0 Underlying: Common Stock · 2,422,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock (the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date. F1 · price: Each share of Series B Preferred Stock (the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock (the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock (the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares are directly held by Everest Aggregator, LP ("Everest"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 16:15 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 1,363,636 | $11.00 | $14,999,996.00 |
DisclosureSEC source: 0001415889-24-025354 · form4-10172024_041001.xml · nonDerivative · entry 2 Enavate Sciences GP, LLC · CIK 0001953107 · 10% owner Everest Aggregator, LP · CIK 0002040426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Everest Aggregator, LP Disclosed balance after: 3,785,802 F2 · ownership.nature: Shares are directly held by Everest Aggregator, LP ("Everest"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 16:15 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 2,422,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-025354 · form4-10172024_041001.xml · nonDerivative · entry 1 Enavate Sciences GP, LLC · CIK 0001953107 · 10% owner Everest Aggregator, LP · CIK 0002040426 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Everest Aggregator, LP Disclosed balance after: 2,422,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock (the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares are directly held by Everest Aggregator, LP ("Everest"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.